Objective: To summarize the adverse effects of
pegaspargase in the treatment of lymphoid
malignancies and management experience. Methods: Clinical data of patients who received
chemotherapy including
pegaspargase in the Department of Hematology of Beijing Tongren hospital during August 2011 to December 2015 were retrospective analyzed, and the adverse effects of
pegaspargase and the management experience was summarized. Results: A total of 129 patients with 443 times of
pegaspargase used during this period. The common adverse reactions included
allergic reactions in 2 cases (1.6%),
acute pancreatitis in 19 (14.7%) including 6 acute symptomatic
pancreatitis and 13 chemical
pancreatitis with elevated
pancreatin,
hypertriglyceridemia in 15 cases(11.6%),
hyperglycemia in 85 (65.9%),
hypoglycemia in 7 (5.4%), elevated
aminotransferase in 25 (19.4%),
hyperbilirubinemia in 21 (15.5%),
hypoalbuminemia in 62 (48.1%), prolonged APTT in 61 (47.3%), prolonged PT in 22 (17.1%), prolonged TT in 15 (11.6%), hypofibrinogen in 75 (58.1%),
thrombus in 11 (8.5%) and
bleeding in 3 (2.3%). The above adverse reactions were improved by symptomatic treatment of anti
allergy, inhibition of secretion of pancreatic juice,
lipid lowering,
hypoglycemic, liver preservation, supplementation of plasma and hemostasis, respectively. Some serious adverse reactions affected the application of
pegaspargase, even lead to discontinuation of the
aspartate. Conclusion: Though adverse effects associated with
pegaspargase are extensive, most patients can successfully complete the
chemotherapy containing the
pegaspargase with close monitoring and timely treatment.